BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33233857)

  • 1. Peripheral Blood Eosinophilia Is Associated with Poor Outcome Post-Lung Transplantation.
    Kaes J; Van der Borght E; Vanstapel A; Van Herck A; Sacreas A; Heigl T; Vanaudenaerde BM; Godinas L; Van Raemdonck DE; Ceulemans LJ; Neyrinck AP; Vos R; Verleden GM; Verleden SE; Group The Leuven Lung Transplant
    Cells; 2020 Nov; 9(11):. PubMed ID: 33233857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation.
    Verleden SE; Ruttens D; Vandermeulen E; van Raemdonck DE; Vanaudenaerde BM; Verleden GM; Vos R
    Transplantation; 2014 Jan; 97(1):83-9. PubMed ID: 24157472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAL Fluid Eosinophilia Associates With Chronic Lung Allograft Dysfunction Risk: A Multicenter Study.
    Todd JL; Weber JM; Kelly FL; Neely ML; Mulder H; Frankel CW; Nagler A; McCrae C; Newbold P; Kreindler J; Palmer SM
    Chest; 2023 Sep; 164(3):670-681. PubMed ID: 37003354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a post-transplant chronic lung allograft dysfunction classification system.
    Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.
    Combs MP; Xia M; Wheeler DS; Belloli EA; Walker NM; Braeuer RR; Lyu DM; Murray S; Lama VN
    J Heart Lung Transplant; 2020 Aug; 39(8):815-823. PubMed ID: 32360292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.
    Vandermeulen E; Verleden SE; Ruttens D; Moelants E; Mortier A; Somers J; Bellon H; Piloni D; Dupont LJ; Van Raemdonck DE; Proost P; Schols D; Vos R; Verleden GM; Vanaudenaerde BM
    Transpl Immunol; 2015 Sep; 33(1):37-44. PubMed ID: 26168736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
    Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
    J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchoalveolar lavage cytokine-based risk stratification of minimal acute rejection in clinically stable lung transplant recipients.
    Levy L; Huszti E; Ahmed M; Ghany R; Hunter S; Moshkelgosha S; Zhang CYK; Boonstra K; Klement W; Tikkanen J; Singer LG; Keshavjee S; Juvet S; Martinu T
    J Heart Lung Transplant; 2021 Dec; 40(12):1540-1549. PubMed ID: 34215500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Density Analysis Using Quantitative Chest CT for Early Prediction of Chronic Lung Allograft Dysfunction.
    Horie M; Levy L; Houbois C; Salazar P; Saito T; Pakkal M; OʼBrien C; Sajja S; Brock K; Yasufuku K; Keshavjee S; Paul N; Martinu T
    Transplantation; 2019 Dec; 103(12):2645-2653. PubMed ID: 31343572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction.
    Levy L; Moshkelgosha S; Huszti E; Hunter S; Renaud-Picard B; Berra G; Kawashima M; Fernandez-Castillo J; Fuchs E; Dianti M; Ghany R; Keshavjee S; Singer LG; Tikkanen J; Martinu T
    J Heart Lung Transplant; 2023 Aug; 42(8):1152-1160. PubMed ID: 36963446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation.
    Verleden SE; Ruttens D; Vandermeulen E; Bellon H; Dubbeldam A; De Wever W; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM; Verleden GM; Benden C; Vos R
    J Heart Lung Transplant; 2016 Sep; 35(9):1078-84. PubMed ID: 27212563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
    Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Vanaudenaerde BM; Somers J; Schoonis A; Schaevers V; Van Raemdonck DE; Neyrinck A; Dupont LJ; Yserbyt J; Verleden GM; Vos R
    Am J Transplant; 2016 Jan; 16(1):254-61. PubMed ID: 26372728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients-a single-center retrospective cohort study.
    Levy L; Tigert A; Huszti E; Saito T; Mitsakakis N; Moshkelgosha S; Joe B; Boonstra KM; Tikkanen JM; Keshavjee S; Juvet SC; Martinu T
    Transpl Int; 2019 Sep; 32(9):965-973. PubMed ID: 31002407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
    Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
    J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and impact of chronic lung allograft dysfunction after lung transplantation - single-center 14-year experience.
    Nykänen A; Raivio P; Peräkylä L; Stark C; Huuskonen A; Lemström K; Halme M; Hämmäinen P
    Scand Cardiovasc J; 2020 Jun; 54(3):192-199. PubMed ID: 32148103
    [No Abstract]   [Full Text] [Related]  

  • 16. Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis.
    Vanstapel A; Goldschmeding R; Broekhuizen R; Nguyen T; Sacreas A; Kaes J; Heigl T; Verleden SE; De Zutter A; Verleden G; Weynand B; Verbeken E; Ceulemans LJ; Van Raemdonck DE; Neyrinck AP; Schoemans HM; Vanaudenaerde BM; Vos R
    Front Immunol; 2021; 12():661761. PubMed ID: 34122421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial and Erythrocyte Microvesicles From Bronchoalveolar Lavage Fluid Are Elevated and Associated With Outcome in Chronic Lung Allograft Dysfunction.
    Harms A; Fuehner T; Warnecke G; Haverich A; Gottlieb J; Trummer A
    Transplantation; 2015 Nov; 99(11):2394-400. PubMed ID: 26451527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.
    Shino MY; Weigt SS; Li N; Derhovanessian A; Sayah DM; Saggar R; Huynh RH; Gregson AL; Ardehali A; Ross DJ; Lynch JP; Elashoff RM; Belperio JA
    Am J Transplant; 2018 Jan; 18(1):136-144. PubMed ID: 28637080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation on bronchoalveolar lavage cytology is associated with decreased chronic lung allograft dysfunction-free survival.
    Greenland NY; Deiter F; Calabrese DR; Hays SR; Kukreja J; Leard LE; Kolaitis NA; Golden JA; Singer JP; Greenland JR
    Clin Transplant; 2022 Jun; 36(6):e14639. PubMed ID: 35246990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.
    Shino MY; Weigt SS; Li N; Derhovanessian A; Sayah DM; Huynh RH; Saggar R; Gregson AL; Ardehali A; Ross DJ; Lynch JP; Elashoff RM; Belperio JA
    Am J Transplant; 2017 May; 17(5):1294-1303. PubMed ID: 27676455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.